R. David Guyer's most recent trade in EyePoint Pharmaceuticals Inc was a trade of 11,625 Common Stock done at an average price of $10.1 . Disclosure was reported to the exchange on July 12, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Sale of securities on an exchange or to another person at price $ 10.06 per share. | 12 Jul 2024 | 11,625 | 1,850 (0%) | 0% | 10.1 | 116,995 | Common Stock |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 12 Jul 2024 | 6,525 | 13,475 (0%) | 0% | 3.3 | 21,272 | Common Stock |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 6,525 | 6,525 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 12 Jul 2024 | 3,250 | 6,950 (0%) | 0% | 3.5 | 11,375 | Common Stock |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 3,250 | 3,250 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Sale of securities on an exchange or to another person at price $ 10.30 per share. | 03 Jun 2024 | 11,625 | 3,700 (0%) | 0% | 10.3 | 119,705 | Common Stock |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 03 Jun 2024 | 6,525 | 12,075 (0%) | 0% | 3.3 | 21,272 | Common Stock |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 6,525 | 13,050 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 3,250 | 6,500 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 03 Jun 2024 | 3,250 | 15,325 (0%) | 0% | 3.5 | 11,375 | Common Stock |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Sale of securities on an exchange or to another person at price $ 12.65 per share. | 14 May 2024 | 11,625 | 5,550 (0%) | 0% | 12.6 | 147,045 | Common Stock |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 6,525 | 19,575 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 14 May 2024 | 6,525 | 13,925 (0%) | 0% | 3.3 | 21,272 | Common Stock |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 3,250 | 9,750 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.50 per share. | 14 May 2024 | 3,250 | 17,175 (0%) | 0% | 3.5 | 11,375 | Common Stock |
| EyePoint Pharmaceuticals Inc | R. David Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 7,400 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 11,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 4,400 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David R. Guyer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 1,900 (0%) | 0% | 0 | Common Stock |